A Phase II study enrolling 341 patients with moderate-to-severe active SLE revealed that the ABBV-599 high dose (elubrutinib, a selective Bruton tyrosine kinase inhibitor, 60 mg + the JAK1 inhibitor upadacitinib, 30 mg) or upadacitinib (30 mg) attained the primary endpoint, defined as the proportion of patients who achieved an SRI-4 score and a steroid dose ≤ 10 mg daily compared with placebo at week 24; however, the low dose of ABBV-599 (elubrutinib, 60 mg + Upadacitinib, 15 mg) and 60 mg of elsubrutinib alone failed to show effectiveness compared with placebo treatment (98)[(NCT03978520)]. The gene discussed is JAK1; the disease is systemic lupus erythematosus.